This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
- Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities--Phase III Studies
- Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry
- Controversies on the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data
- Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
- The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders
- Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
- PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer
- Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry
- 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry
- Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry
- Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
- Application of FDG-PET in Cervical Cancer and Endometrial Cancer: Utility and Future Prospects
- Intended Versus Inferred Care After PET Performed for Initial Staging in the National Oncologic PET Registry
- The Medical Imaging & Technology Alliance Conference on Research Endpoints Appropriate for Medicare Coverage of New PET Radiopharmaceuticals
- The Lack of Evidence for PET or PET/CT Surveillance of Patients with Treated Lymphoma, Colorectal Cancer, and Head and Neck Cancer: A Systematic Review
- Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts
- Nuclear Medicine at a Crossroads
- Contribution of Imaging to Cancer Care Costs
- Incidental Diagnosis of Thrombus Within an Aneurysm on 18F-FDG PET/CT: Frequency in 926 Patients
- Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
- Whole-Body 18F-FDG PET/CT: The Need for a Standardized Field of View--A Referring-Physician Aid
- Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
- The PET/CT Report: The Most Important Part of the Study
- PET and PET/CT Reports: Observations from the National Oncologic PET Registry
- Superiority of Magnetic Resonance Imaging Over Conventional Radiographs in Multiple Myeloma
- Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
- A new pet for myeloma
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types